Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease
Published inEuropean Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 9, p. 1546-1556
Publication date2018
Abstract
Keywords
- Amyotrophic Lateral Sclerosis/diagnostic imaging
- Brain
- Fluorodeoxyglucose F18
- Humans
- Huntington Disease/diagnostic imaging
- Positron-Emission Tomography
- Radiopharmaceuticals
Affiliation entities
Research groups
Citation (ISO format)
AGOSTA, Federica et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease. In: European Journal of Nuclear Medicine and Molecular Imaging, 2018, vol. 45, n° 9, p. 1546–1556. doi: 10.1007/s00259-018-4033-0
Main files (1)
Article (Published version)
Identifiers
- PID : unige:114050
- DOI : 10.1007/s00259-018-4033-0
- PMID : 29717332
ISSN of the journal1619-7070